NCT03134872View on ClinicalTrials.gov

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

PHASE3CompletedINTERVENTIONAL
Enrollment

419

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

July 27, 2019

Study Completion Date

August 29, 2019

Conditions
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseaseNeoplasms by SiteNeoplasm, BronchialCarcinoma, Bronchogenic
Interventions
BIOLOGICAL

SHR-1210

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

DRUG

Carboplatin

Carboplatin

DRUG

Pemetrexed

Pemetrexed

Trial Locations (1)

200433

Tongji University, Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03134872 - A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | Biotech Hunter | Biotech Hunter